期刊文献+

奥沙利铂联合5-FU、CF治疗老年Ⅲ期结肠癌的临床分析 被引量:5

The Clinical Analysis of Oxaliplatin Combined with 5-FU, CF for the Treatment of Stage Ⅲ Colon Cancer in Eldly Patients
下载PDF
导出
摘要 目的评价奥沙利铂联合氟尿嘧啶5-FU、亚叶酸钙CF治疗老年Ⅲ期结肠癌(术后)的临床疗效及不良反应。方法 10例老年Ⅲ期结肠癌均为术后采用奥沙利铂联合氟尿嘧啶5-FU、亚叶酸钙CF(FOLFOX4方案)化疗,至少6个周期评价疗效。结果所有患者均可评价疗效和不良反应,其中CR2例、PR5例、SD3例、PD0例,总有效率达70.0%。主要的不良反应为骨髓抑制、消化道反应、神经毒性(主要是感觉神经毒性),毒副反应均可耐受。结论奥沙利铂联合氟尿嘧啶5-FU、亚叶酸钙CF(FOLFOX4方案)治疗老年Ⅲ期结肠癌(术后)有效率较高,不良反应可耐受。 Objective To evaluate the clinical effect and adverse reaction of Oxaliplatin combined with 5-FU, CF for the treatment of stage Ⅲ colon cancer in eldly patients. Methods 10 eldly patients with stage Ⅲ colon cancer were given the therapy of Oxaliplatin combiened with 5-FU, CF after surgery, the clinical effect was evaluated after at least 6 cycles. Results' All the patients were evaluated the effect and adverse reaction, among whom CR: 2 cases, PR: 5 cases, SD: 3 cases, PD: 0 case, the total effective rate was 70.0%. The main adverse reaction were myelosuppression, gastrointestinal reactions, neurotoxicity (mainly sensory nerve toxicity), all the cases could endure the main adverse reaction. Conclusion The effective rate of FOLFOX4 program for the treatment of stage Ⅲ colon cancer in eldly patients is high, the adverse reaction can be endured.
作者 李康保
出处 《临床医学工程》 2011年第3期345-346,共2页 Clinical Medicine & Engineering
关键词 Ⅲ期结肠癌 老年 奥沙利铂 联合化疗 Stage Ⅲ colon cancer Eldly patients Oxaliplatin Combination chemotherapy
  • 相关文献

参考文献5

二级参考文献55

  • 1[1]de Gramont A,Louvet C,Andre T,et al.Modulation of 5-fluorouracil with folinic acid in advanced colorectal cancers.Grouped 'etude et de recherche sur les cancers de l'ovaire et digestifs (GERCOD).Rev Med Interne,1997,18 Suppl 4:372S 被引量:1
  • 2[2]Van Cutsem E,Findlay M,Osterwalder B,et al.Capecitabine,an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer:Results of a randomized phase Ⅱ study.J Clin Oncol,2000,18 (6):1337 被引量:1
  • 3[3]Cvitkovic E,Bekradda M.Oxaliplatin:A new therapeutic option in colorectal cancer.Semin Oncol,1999,26(6):647 被引量:1
  • 4[4]Cassidy,G.A.Bjarnason,T.Hickish,et al.Randomized double blind (DB) placebo (Plcb) controlled phase Ⅲ study assessing the efficacy of xaliproden (X) in reducing the cumulative peripheral sensory neuropathy (PSN) induced by the oxaliplatin (Ox) and 5-FU/LV combination (FOLFOX4) in first-line treatment of patients (pts) with metastatic colorectal cancer (MCRC) J Clin Oncol (Meeting Abstracts),2006,24:3507 被引量:1
  • 5[5]Firvida JL,Irigoyen A,Vazquez-Estevez S,et al.Phase Ⅱ study of irinotecan as first-line chemotherapy for patients with advanced colorectal carcinoma.Cancer,2001,91(4):704 被引量:1
  • 6[6]Van Cutsem E,Cunningham D,Ten Bokkel Huinink,et al.Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU).Eur J Cancer,1999,35 (1):54 被引量:1
  • 7[7]Kouroussis C,Souglakos J,Kakolyris S,et al.Oxaliplatin in combination with infusional 5-fluorouracil and leucovorin every 2 weeks as first-line treatment in patients with advanced colorectal cancer:A phase Ⅱ study.Oncology,2001,61 (1):36 被引量:1
  • 8[8]Carrato A,Gallego J,Diaz-Rubio E.Oxaliplatin:results in colorectal carcinoma.Crit Rev Oncol Hematol,2002,44(1):29 被引量:1
  • 9[9]Maindrault-Goebel F,Lledo G,Chibaudel B,et al.OPTIMOX2,a large randomized phase Ⅱ study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC).A GERCOR study.J Clin Oncol (Meeting Abstracts),2006,24:3504 被引量:1
  • 10[ 10 ] 被引量:1

共引文献376

同被引文献26

  • 1Scott GK, Goga A,Bhaumik D, et al. Coordinatesuppression of ERBB2 and ERBB3 by enforced expressionof micro-RNA miR425b[ J]. J Biol Chen,2007 ,282(2):1479 - I486. 被引量:1
  • 2Slaby 0,Svoboda M,Fabian P,et al. Altered expression ofmiR-21 , miR-31,miR-143 and miR-145 is related toclinicopathologic features of colorectal cancer [ J ].Oncology,2007,72(5-6) :397 -402. 被引量:1
  • 3Faltejskova P, Besse A, Sevcikova S,et al. Clinicalcorrelations of miR-21 expression in colorectal cancerpatients and effects of its inhibition on DLD1 colon cancercells [ J ]. Int J Colorectal Dis, 2012, 27 ( 11 ) : 1401 -1408. 被引量:1
  • 4Xu L,Huang Y, Chen D, et al. Downregulation of miR-21 increases cisplatin sensitivity of non-small-cell lungcancer[ J]. Cancer Genet ,2014,207(5) :214 - 220. 被引量:1
  • 5Meng F,Henson R,Lang M,et al. I nvolvement of humanmicro-RNA in growth and response to chemotherapy inhuman cholangio carcinoma cell lines [ J ]. Gastroenterolo-gy,2006,130(7) :2113 -2129. 被引量:1
  • 6Ren W, Wang X, Gao L, et al. MiR-21 modulateschemosensitivity of tongue squamous cell carcinoma cellsto cisplatin by targeting PDCD4[ J]. Mol Cell Biochem,2014,390(1-2) :253 -262. 被引量:1
  • 7Hwang JH, Voortman J, Giovannetti E, et al.Identification of microRNA-21 as a biomarker forchemoresistance and clinical outcome following adjuvanttherapy in resectable pancreatic cancer [ J]. PLoS One,2010,5(5) :el0630. 被引量:1
  • 8Tomimaru Y,Eguchi H,Nagano H,et al. MicroRNA-21induces resistance to the anti-tumour effect of interferon5-fluorouracil in hepatocellular carcinoma cells[ J]. Br JCancer,2010,103( 10) : 1617 -1626. 被引量:1
  • 9Wong ST, Zhang XQ, Zhuang JT,et al. MicroRNA-21inhibition enhances in vitro chemosensitivity of temozolo-mide-resistant glioblastoma cells [ J ]. Anticancer Res,2012,32(7) :2835 -2841. 被引量:1
  • 10Deng J,Lei W,Fu JC,et al. Down regulation of miR-21increases cisplatin sensitivity of non-small-cell lungcancer[ J] . Cancer Genet,2014,207(5) :214 - 220. 被引量:1

引证文献5

二级引证文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部